| 郑 鸣,叶明翔,宋 勇.非小细胞肺癌合并恶性心包积液的治疗进展[J].肿瘤学杂志,2021,27(3):180-185. |
| 非小细胞肺癌合并恶性心包积液的治疗进展 |
| Advances in Treatment of Non-small Cell Lung Cancer Patients with Malignant Pericardial Effusion |
| 投稿时间：2020-11-11 |
| DOI：10.11735/j.issn.1671-170X.2021.03.B005 |
|
 |
| 中文关键词: 恶性心包积液 非小细胞肺癌 治疗策略 |
| 英文关键词:malignant pericardial effusion non-small cell lung cancer therapeutic strategy |
| 基金项目:国家自然科学基金青年基金项目（81802301） |
|
| 摘要点击次数: 953 |
| 全文下载次数: 162 |
| 中文摘要: |
| 摘 要：恶性心包积液是晚期非小细胞肺癌的严重并发症，显著影响患者的生存。晚期非小细胞肺癌合并恶性心包积液的治疗进展缓慢，目前主要治疗手段是局部治疗或联合全身抗肿瘤治疗。局部治疗包括心包积液引流、心包腔内药物灌注、放疗和热疗；全身抗肿瘤治疗包括化疗，靶向治疗、抗血管治疗和免疫治疗等。全文对晚期非小细胞肺癌合并恶性心包积液治疗方案进行综合分析，以期为临床处理恶性心包积液提供理论和实践依据。 |
| 英文摘要: |
| Abstract：Malignant pericardial effusion(MPCE) is a serious complication of advanced non-small cell lung cancer(NSCLC). Patients with MPCE often have unfavorable prognosis，unfortunately，therapeutic strategies for MPCE are rather limited. To date，local therapies or combined with systemic therapies remain to be the main treatment for MPCE. Local therapies mainly include the drainage of pericardial effusion，intrapericardial-infusion of drugs，radiotherapy，and hyperthermia. Meanwhile，systemic combinational therapies are composed of chemotherapy，targeted therapy，anti-vascular therapy and immunotherapy. The safety and efficacy of these therapies in patients with MPCE have been evaluated in previous clinical studies. This article systemically and comprehensively analyzes these results to provide insights into the therapeutic strategies for advanced NSCLC patients with MPCE. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |